Global Medical Aesthetic Products Market Research Report Information by Product (Botulinum Toxin, Dermal Fillers), by Application, by Gender, by End User, by Region Forecast Till 2032
세계의 메디컬 에스테틱 제품 시장 규모는 2023년 89억 7,127만 달러를 기록했습니다. 2024년 97억 234만 달러에서 예측 기간 동안 10.8%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2032년에는 220억 3,240만 달러의 규모로 성장할 것으로 예상되고 있습니다.
메디컬 에스테틱 제품 시장은 보톡스와 더말 필러의 수용과 도입 증가, 최소 침습적 미용 시술의 인기 증가에 의해 자극되고 있습니다.
메디컬 에스테틱 제품 시장은 침습성이 낮은 미용 시술의 보급으로 크게 확대되고 있습니다. 보톡스와 피부 필러는 수술에 흔한 긴 회복 기간을 거치지 않고 외모를 향상시키는 효과적인 솔루션을 찾는 소비자들 사이에서 인기를 얻고 있습니다. 이러한 치료법은 즉각적이고 불쾌감이 적기 때문에 예방적 치료를 요구하는 젊은 사람들을 포함한 다양한 사람들에게 매력적입니다. 이러한 최소 침습적적 선택의 편리성과 안전성은 기술과 제제의 진보와 함께 매우 매력적입니다. 시장의 전반적인 확대는 소셜 미디어와 인플루언서의 지지를 통한 장점에 대한 인지도의 지속적인 향상에 의해 추진될 것으로 예상되며, 이러한 미용적 개입에 대한 수요에 기여할 것으로 기대됩니다.
지역별 전망
북미 시장 점유율은 2023년에 가장 높았으며, 2032년에는 85억 9,484만 달러에 이를 것으로 예상됩니다. 반면 아시아태평양은 예측 기간 동안 12.46%에서 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 유럽의 메디컬 에스테틱 제품 시장은 2023년에 25억 4,523만 달러로 평가되었고, 예측 기간 중에는 11.62%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 전망되고 있습니다.
본 보고서에서는 세계의 메디컬 에스테틱 제품 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이와 예측, 각종 구분·지역/주요 국가별 분석, 경쟁환경, 주요기업의 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 성장 촉진요인
- 최소 침습적 미용 수술의 인기 증가
- 피부 필러와 보톡스의 승인과 발매 증가
- 성장 억제요인
- 피부 필러 및 보톡스와 관련된 부작용
- 피부 필러와 관련된 미국 식품의약국(FDA) 경고 서한
- 가짜 및 위조 버전의 보톡스 필러
- 기회
제5장 시장 요인 분석
- Porter's Five Forces 분석
- COVID-19가 메디컬 에스테틱 제품 시장에 미치는 영향
- 소비자의 기호
- 규제 상황
- 시장 동향
- 가격 분석
- 트레이더 및 유통업체 : 지역/국가
- 제조 업체 리스트
- 지역별 절차 분석(2019-2023년)
제6장 메디컬 에스테틱 제품 시장 : 제품별
- 개요
- 보툴리눔 톡신(보톡스)
- 피부 필러
- 히알루론산
- 칼슘 하이드록실라파타이트
- 폴리-L-락틱산
- 폴리메틸-메타크릴레이트 마이크로스피어(PMMA)
- 폴리알킬이미드
- 기타
제7장 메디컬 에스테틱 제품 시장 : 용도별
- 개요
- 제모
- 스킨 리서페이싱
- 안면 회춘
- 지방 흡입
- 안면 성형
- 피부 이식
- 주름 감소
- 기타
제8장 메디컬 에스테틱 제품 시장 : 성별
제9장 메디컬 에스테틱 제품 시장 : 최종 사용자별
- 개요
- 병원·피부과 의원
- 메디컬 스파
- 미용 클리닉
제10장 메디컬 에스테틱 제품 시장 : 지역별
제11장 경쟁 구도
- 시장 점유율 분석 : 피부 필러
- 시장 점유율 분석 : 보툴리눔 툭신(보톡스)
- 경쟁 대시보드
- 공개 기업의 주식 개요
- 비교 분석 : 주요 기업의 재무
- 주요 전개 및 성장 전략
제12장 기업 프로파일
- REVANCE THERAPEUTICS
- ABBVIE, INC.
- SUNEVA MEDICAL
- BIOXIS PHARMACEUTICALS
- MERZ PHARMA
- GALDERMA
- SINCLAIR
- MEDYTOX
- TEOXANE
- DR. KORMAN
제13장 데이터 인용
KTH
Global Medical Aesthetic Products Market Research Report Information by Product (Botulinum Toxin (Botox), Dermal Fillers), by Application (Hair Removal, Skin Resurfacing, Facial Rejuvenation, Liposuction, Facelifts, Skin Grafting, Wrinkle Reduction, Others), by Gender (Male, Female), by End User (Hospitals & Dermatological Clinics, Medical Spas, Beauty Clinics), by Region (North America, Europe, Asia-Pacific, Rest of the World) Forecast Till 2032
Market Overview
The market size of medical aesthetic products was estimated to be USD 8,971.27 million in 2023. It is anticipated that the Global Medical Aesthetic Products industry will expand at a compound annual growth rate (CAGR) of 10.8% from USD 9,702.34 Million in 2024 to USD 22,032.40 Million by 2032. This expansion is anticipated to transpire during the forecast period of 2024 to 2032.
The Medical Aesthetic Products Market is being stimulated by the increasing acceptance and introduction of botox and dermal fillers, as well as the increasing popularity of minimally invasive cosmetic procedures.
The Medical Aesthetic Products Market is expanding significantly due to the increasing prevalence of minimally invasive cosmetic procedures. Botox and dermal fillers have gained popularity among consumers who are seeking effective solutions to enhance their appearance without the protracted recovery period typically associated with surgical options. The immediate results and minimal discomfort of these procedures make them appealing to a diverse spectrum of individuals, including younger individuals who are pursuing preventative treatments. The convenience and safety profile of these minimally invasive options, in conjunction with advancements in techniques and formulations, have made them highly appealing. The overall expansion of the market is anticipated to be driven by the ongoing increase in awareness of the benefits through social media and influencer endorsements, which is expected to contribute to the demand for these cosmetic interventions.
Market segment insights
Based on product, the Medical Aesthetic Products Market has been divided into botulinum toxin (Botox) and dermal fillers. A further division of botulinum toxin (Botox) is Type A and Type B. Dermal fillers are further classified as hyaluronic acid, calcium hydroxylapatite, poly-l-lactic acid, polymethyl-methacrylate microspheres (PMMA), and polyalkylimide.
The Market has been categorized into the following categories based on application: hair removal, skin resurfacing, facial rejuvenation, liposuction, facelifts, skin grafting, wrinkle reduction, and others.
The Medical Aesthetic Products Market has been divided into male and female segments according to gender.
The market has been divided into three categories based on the end user: hospitals and dermatological clinics, medical retreats, and cosmetic clinics.
Regional Perspectives
According to region, the Medical Aesthetic Products Market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America's market share was the highest in 2023 and is anticipated to reach USD 8,594.84 million by 2032. Nevertheless, it is anticipated that the Asia-Pacific region will experience the most substantial compound annual growth rate (CAGR) of 12.46% during the forecast period. The Europe Medical Aesthetic Products Market was valued at USD 2,545.23 million in 2023 and is expected to experience a compound annual growth rate (CAGR) of 11.62% during the forecast period. The additional segments of Europe include the United Kingdom, Italy, France, Spain, and Germany. The Asia-Pacific Medical Aesthetic Products Market was valued at USD 1,631.78 million in 2023 and is expected to experience a compound annual growth rate (CAGR) of 12.46% during the forecast period. Subregions of the Asia-Pacific region include China, India, Japan, South Korea, Australia, New Zealand, and the Rest of Asia-Pacific.
Major Players
The Medical Aesthetic Products Market is primarily participated in by Suneva Medical, Abbvie, Inc., Bioxis Pharmaceuticals, Merz Pharma, Galderma, Sinclair, Medytox, Teoxane, and Dr. Korman.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
- 3.1 OVERVIEW
- 3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
- 3.3 PURCHASED DATABASE:
- 3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
- 3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
- 3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
- 3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
- 3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
- 4.1 INTRODUCTION
- 4.2 DRIVERS
- 4.2.1 INCREASING POPULARITY OF MINIMALLY INVASIVE COSMETIC PROCEDURES
- 4.2.2 RISING APPROVAL AND LAUNCH FOR DERMAL FILLERS AND BOTOX
- 4.3 RESTRAINTS
- 4.3.1 SIDE EFFECTS ASSOCIATED WITH DERMAL FILLERS AND BOTOX
- 4.3.2 FOOD AND DRUG ADMINISTRATION (FDA) WARNING LETTER ASSOCIATED WITH THE DERMAL FILLERS
- 4.3.3 FAKE AND COUNTERFEIT VERSION OF BOTOX FILLERS
- 4.4 OPPORTUNITY
- 4.4.1 GROWING GERIATRIC POPULATION
5 MARKET FACTOR ANALYSIS
- 5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
- 5.2 IMPACT OF COVID-19 ON MEDICAL AESTHETIC PRODUCTS MARKET
- 5.3 CONSUMER PREFERENCE
- 5.4 REGULATORY LANDSCAPE
- 5.4.1 NORTH AMERICA
- 5.4.2 EUROPE
- 5.4.3 ASIA-PACIFIC
- 5.4.4 MIDDLE EAST & AFRICA
- 5.5 MARKET TRENDS IN THE MEDICAL AESTHETIC PRODUCTS MARKET
- 5.6 PRICING ANALYSIS
- 5.7 LIST OF TRADERS AND DISTRIBUTORS REGION/COUNTRY
- 5.8 LIST OF MANUFACTURERS
- 5.9 PROCEDURE ANALYSIS ON REGIONAL LEVEL (2019-2023)
6 MEDICAL AESTHETIC PRODUCTS MARKET, BY PRODUCT
- 6.1 OVERVIEW
- 6.2 BOTULINUM TOXIN (BOTOX)
- 6.2.1 TYPE A
- 6.2.2 TYPE B
- 6.3 DERMAL FILLERS
- 6.3.1 HYALURONIC ACID
- 6.3.2 CALCIUM HYDROXYLAPATITE
- 6.3.3 POLY-L-LACTIC ACID
- 6.3.4 POLYMETHYL-METHACRYLATE MICROSPHERES (PMMA)
- 6.3.5 POLYALKYLIMIDE
- 6.3.6 OTHERS
7 MEDICAL AESTHETIC PRODUCTS MARKET, BY APPLICATION
- 7.1 OVERVIEW
- 7.2 HAIR REMOVAL
- 7.3 SKIN RESURFACING
- 7.4 FACIAL REJUVENATION
- 7.5 LIPOSUCTION
- 7.6 FACELIFTS
- 7.7 SKIN GRAFTING
- 7.8 WRINKLE REDUCTION
- 7.9 OTHERS
8 MEDICAL AESTHETIC PRODUCTS MARKET, BY GENDER
- 8.1 OVERVIEW
- 8.2 MALE
- 8.3 FEMALE
9 MEDICAL AESTHETIC PRODUCTS MARKET, BY END USER
- 9.1 OVERVIEW
- 9.2 HOSPITALS & DERMATOLOGICAL CLINICS
- 9.3 MEDICAL SPAS
- 9.4 BEAUTY CLINICS
10 MEDICAL AESTHETIC PRODUCTS MARKET, BY REGION
- 10.1 OVERVIEW
- 10.2 NORTH AMERICA
- 10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 SOUTH KOREA
- 10.4.5 AUSTRALIA
- 10.4.6 NEW ZEALAND
- 10.4.7 REST OF ASIA PACIFIC
- 10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA
- 10.5.3.1 ARGENTINA
- 10.5.3.2 BRAZIL
- 10.5.3.3 COLOMBIA
- 10.5.3.4 REST OF LATIN AMERICA
11 COMPETITIVE LANDSCAPE
- 11.1 INTRODUCTION
- 11.2 MARKET SHARE ANALYSIS, DERMAL FILLERS,
- 11.3 MARKET SHARE ANALYSIS, BOTULINUM TOXIN (BOTOX),
- 11.4 COMPETITOR DASHBOARD
- 11.5 PUBLIC PLAYERS STOCK SUMMARY
- 11.6 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
- 11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.1.1 PRODUCT LAUNCH
- 11.1.2 PRODUCT APPROVAL
- 11.1.3 AGREEMENT
- 11.1.4 EXPANSION
12 COMPANY PROFILES
- 12.1 REVANCE THERAPEUTICS
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
- 12.2 ABBVIE, INC.
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
- 12.3 SUNEVA MEDICAL
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
- 12.4 BIOXIS PHARMACEUTICALS
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGIES
- 12.5 MERZ PHARMA
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
- 12.6 GALDERMA
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
- 12.7 SINCLAIR
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
- 12.8 MEDYTOX
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
- 12.9 TEOXANE
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
- 12.10 DR. KORMAN
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES
13 DATA CITATIONS
